Journal
RADIOTHERAPY AND ONCOLOGY
Volume 139, Issue -, Pages 11-17Publisher
ELSEVIER IRELAND LTD
DOI: 10.1016/j.radonc.2019.04.008
Keywords
FLASH-radiotherapy; Normal tissue protection; Differential effect; Clinical trial
Funding
- Fond'action, FNS [FNS/ANR CR32I3L_156924, 31003A_156892]
- ISREC Foundation
- Ecole Normale Superieure de Cachan fellowship (MESR)
- FNS/ANR [CR32I3L_156924]
- Swiss National Science Foundation (SNF) [CR32I3L_156924] Funding Source: Swiss National Science Foundation (SNF)
Ask authors/readers for more resources
Over the past decades, technological advances have transformed radiation therapy (RT) into a precise and powerful treatment for cancer patients. Nevertheless, the treatment of radiation-resistant tumors is still restricted by the dose-limiting normal tissue complications. In this context, FLASH-RT is emerging in the field. Consisting of delivering doses within an extremely short irradiation time, FLASH-RT has been identified as a promising new tool to enhance the differential effect between tumors and normal tissues. Indeed, preclinical studies on various animal models and a veterinarian clinical trial have recently shown that compared to conventional dose-rate RT, FLASH-RT could control tumors while minimizing normal tissue toxicity. In the present review, we summarize the main data supporting the clinical translation of FLASH-RT and explore its feasibility, the key irradiation parameters and the potential technologies needed for a successful clinical translation. (C) 2019 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available